title: Electrophysiological effects of the co-administration of escitalopram and bupropion on rat serotonin and norepinephrine neurons.
abstract: Clinical studies indicate that addition of bupropion to selective serotonin (5-HT) reuptake inhibitors (SSRIs) provides incremental benefit over SSRI monotherapy in depression. This study was designed to investigate the effects of co-administration of bupropion with escitalopram on the firing rate of 5-HT and norepinephrine (NE) neurons in anesthetized rats. Escitalopram (10 mg/kg/day x 2 days), given via subcutaneously (s.c.) implanted minipumps, decreased the firing of 5-HT and NE neurons by 70% and 55%, respectively. The firing of 5-HT neurons, unlike that of NE neurons, recovered after the 14-day escitalopram regimen. Bupropion, injected once daily (30 mg/kg/day, s.c. x 2 days), did not increase 5-HT firing but decreased that of NE by 55%. After 14 days of repeated bupropion administration, 5-HT firing was increased by 50%, and NE firing was back to baseline. Co-administration of escitalopram and bupropion doubled 5-HT firing after 2 and 14 days, whereas NE neurons were inhibited by 60% after 2 days, but partially recovered after 14 days. The responsiveness of 5-HT(1A) autoreceptors was significantly attenuated in the combination-treated rats after 2 days, indicating an early desensitization. These results provide support for contributions from 5-HT and NE mechanisms for enhanced effectiveness of combination of SSRI and bupropion treatment.
authors: University of Ottawa, Institute of Mental Health Research, Ottawa Ontario, Canada. ramez.ghanbari@rohcg.on.ca
authors: R
authors: R
authors: Ghanbari
authors: M
authors: M
authors: El Mansari
authors: P
authors: P
authors: Blier
mesh_terms: D000818:Animals; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000494:pharmacology; D017660:Autoreceptors / Q000187:drug effects / Q000378:metabolism; D016642:Bupropion / Q000008:administration & dosage / Q000494:pharmacology*; D015283:Citalopram / Q000008:administration & dosage / Q000494:pharmacology*; D018765:Dopamine Uptake Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004594:Electrophysiology; D008297:Male; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D044402:Receptor, Serotonin, 5-HT2A / Q000187:drug effects / Q000378:metabolism; D012701:Serotonin / Q000378:metabolism*; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D013997:Time Factors
chemical_list: D018687:Antidepressive Agents, Second-Generation; D017660:Autoreceptors; D016642:Bupropion; D015283:Citalopram; D018765:Dopamine Uptake Inhibitors; D009638:Norepinephrine; D044402:Receptor, Serotonin, 5-HT2A; D012701:Serotonin; D017367:Selective Serotonin Reuptake Inhibitors